SRP-9001 with imlifidase in DMD patients with pre-existing AAVrh74 antibodies

Phase 1, open-label, single-arm trial of delandistrogene moxeparvovec in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Primary endpoints: Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression as Measured by Western Blot Adjusted by Muscle Content at 12 weeks, Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression in Biopsied Muscle as Measured by Immunofluorescence Fiber Intensity at 12 weeks and 2 more. Started Jan 2024; status: terminated.